Author: p539124

08 February, 2023 in Allgemein

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

04 October, 2022 in Allgemein

Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming

19 September, 2022 in Uncategorized

Pantherna among Pharma Trend award winners

05 September, 2022 in Allgemein

Pantherna Therapeutics collaborates with Charité – Universitätsmedizin Berlin to investigate the potential of therapeutic mRNA in autoimmune disease

25 July, 2022 in Uncategorized

Meet Pantherna Therapeutics at BIO-Europe 2022

11 January, 2022 in Uncategorized

Pantherna Therapeutics secures EUR 4.0 Mio. follow-on financing to advance its therapeutic mRNA development programs 

15 November, 2021 in Allgemein

Astellas and Pantherna Enter into Technology Evaluation Agreement for Research of mRNA-based Regenerative Medicine.

28 May, 2021 in Allgemein

Pantherna Therapeutics to be granted 2.2 millions EFRE public funding.

12 June, 2020 in Allgemein

Pantherna Therapeutics GmbH signs an agreement for technology evaluation with Astellas Innovation Management LLC to evaluate Pantherna’s lipid nanoparticle transport system and mRNA molecules.

02 April, 2020 in Allgemein

Successful follow-up financing for Pantherna Therapeutics’ development programs to fight Acute Respiratory Distress Syndrome